FASTinov and Quilaban Showcase Revolutionary Ultra Rapid Antimicrobial Susceptibility Test at the XIII Portuguese National Clinical Pathology Congress in Algarve
March 25th 2024
(Algarve, Portugal) – FASTinov proudly announces its recent participation alongside Quilaban at the XIII edition of the esteemed Portuguese National Clinical Pathology Congress held in Almancil, Algarve. The congress, which convened renowned clinicians, researchers, and industry experts, provided an invaluable platform for FASTinov and Quilaban to showcase their groundbreaking ultra-rapid Antimicrobial Susceptibility Test (2-hour AST), which is poised to revolutionize diagnostic practices in bloodstream infections and sepsis.
Having taken place from 7 to 9 March, the Clinical Pathology Congress served as an opportune moment for FASTinov to introduce its cutting-edge technology to an audience deeply invested in advancing diagnostic methodologies. As attendees explored the diverse array of exhibits and presentations, the joint presence of FASTinov and Quilaban at the congress stand underscored their shared commitment to combatting antimicrobial resistance and improving bloodstream infection and sepsis patient care across Portugal and beyond.
“Participating in the Clinical Pathology Congress alongside our esteemed distributor allowed us to collectively showcase the transformative potential of our ultra-rapid AST in addressing the critical challenge of antimicrobial resistance,”
“We were thrilled to engage with clinicians, pathologists, and industry leaders, demonstrating how our products can enhance diagnostic workflows and optimize treatment strategies.”
By delivering results in under 2 hours, FASTinov’s products can provide an antibiogram in the same shift when the blood culture flags positive. Engaging discussions, informative presentations, and insightful interactions further highlighted the significance of same-shift results in shaping the future of diagnostic practices.
As FASTinov and Quilaban continue to lead the charge in biotechnological innovation, their participation in the Clinical Pathology Congress marks a significant milestone in their collective mission to combat antimicrobial resistance and elevate the standards of patient care.
About FASTinov
FASTinov is a leading innovator in rapid antimicrobial susceptibility testing, dedicated to revolutionizing patient care in sepsis contexts. With a mission to provide actionable same-shift results, FASTinov’s cutting-edge technology offers healthcare professionals unprecedented insights for targeted treatment decisions.
- For media inquiries, please contact: info@fastinov.com
Share with friends
© 2022